ESKEW MICHAEL L
Known title: DirectorCIK: 0001227734
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Eli Lilly gets EMA backing for Foundayo obesity pill. The European Medicines Agency panel issued a positive opinion on Lilly's Foundayo pill for obesity and type 2 diabetes, clearing a regulatory hurdle for the drug. Recent coverage also notes Lilly's broader pipeline beyond Zepbound and rising competitive pressure on Novo Nordisk. In parallel, the company's largest shareholder announced a $347 million stock sale, adding another layer of market interest.
Transaction History
| MMM | ▲ Buy | Grant | 452 | $44K | 5/3/2024 | View on chart |
| MMM | ▲ Buy | Grant | 456 | $44K | 1/26/2024 | View on chart |
| MMM | ▲ Buy | Grant | 494 | $44K | 10/27/2023 | View on chart |
| MMM | ▲ Buy | Grant | 393 | $44K | 7/28/2023 | View on chart |
| MMM | ▲ Buy | Grant | 1,808 | $185K | 5/9/2023 | View on chart |
| MMM | ▲ Buy | Grant | 415 | $44K | 4/28/2023 | View on chart |
| MMM | ▲ Buy | Grant | 385 | $44K | 1/27/2023 | View on chart |
| MMM | ▲ Buy | Grant | 356 | $44K | 10/28/2022 | View on chart |
| MMM | ▲ Buy | Grant | 312 | $44K | 7/29/2022 | View on chart |
| MMM | ▲ Buy | Grant | 1,214 | $185K | 5/10/2022 | View on chart |
| MMM | ▲ Buy | Grant | 297 | $44K | 4/29/2022 | View on chart |
| MMM | ▲ Buy | Grant | 257 | $44K | 1/28/2022 | View on chart |
| LLY | ▲ Buy | Grant | 677 | $175K | 11/15/2021 | View on chart |
| MMM | ▲ Buy | Grant | 243 | $44K | 10/29/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
3M to challenge $1.4B Australian PFAS lawsuit ahead of Q3 earnings
3M is preparing to challenge Australia's $1.4 billion PFAS contamination lawsuit, a major legal development for the company. At the same time, market participants are looking ahead to 3M's upcoming third-quarter earnings, with Wall Street projections offering insights into key metrics. The stock is currently trading within its 52-week range, with an average analyst target of $186.15.
3M to challenge $1.4B Australian PFAS lawsuit ahead of Q3 earnings. 3M is preparing to challenge Australia's $1.4 billion PFAS contamination lawsuit, a major legal development for the company. At the same time, market participants are looking ahead to 3M's upcoming third-quarter earnings, with Wall Street projections offering insights into key metrics. The stock is currently trading within its 52-week range, with an average analyst target of $186.15.